fingolimod hydrochloride has been researched along with Communicable Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hartung, HP; Loebermann, M; Reisinger, EC; Winkelmann, A; Zettl, UK | 1 |
1 review(s) available for fingolimod hydrochloride and Communicable Diseases
| Article | Year |
|---|---|
Disease-modifying therapies and infectious risks in multiple sclerosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Communicable Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Risk Factors | 2016 |